Sponsors
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Blog
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?26 May 2011
White Papers
Focus Area: Drug Discovery & Development
A national asset
Dave Shanahan shows us how a country as relatively small as Ireland continues to push the industry in every possible context – and with the biggest possible heart.
With David Beyerlein of MicroConstants, Inc. and Dominic Moore of Waters Corporation
With David Beyerlein of MicroConstants, Inc. and Dominic Moore of Waters Corporation
Transforming oncology clinical development: A new path to innovation
Given the staggering statistics on cancer rates, there is a renewed emphasis on cancer research and development—with more than 1,000 oncology compounds currently in development and a significant share of the overall industry R&D spend dedicated to oncology. Historically, the rewards have been big. Blockbuster drugs Avastin, Rituxan, Herceptin and at least 7 others each generate more than $1 billion in annual global sales. However, the development risks are substantial and growing.
The life cycle of the life science
In a quiet industrial complex in suburban St. Louis, something is stirring: the growth of recombinant proteins and monoclonal antibodies, as well as diagnostic test kits for academic and industrial research.
The new gold standard
Amgen has set the standard once again by producing a new Gold Standard in therapy for bone metastases from solid tumours. So what does it mean for patients worldwide?
Source: www.ngpharma.com© 2012 GDS Publishing Ltd. All rights reserved.